Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0598934 (tumor growth)
 58,965 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effects of the specific active cancer immunotherapy utilizing autologous tumor tissue particles polymerise with ethylchlorformiate, and used in combination with PPD tuberculin, were studied on the growth of chloroma in an inbred strain of Wistar rats. As control animals, rats not immunised, or immunised with autologous muscle tissue polymer + PPD, or PPD alone, were studied. A clear-cut enhancement of tumor growth was observed in the group of animals receiving the tumor polymer, as evidenced by the largest tumors, the lowest incidence of tumor rejection and the lack of histological signs of host response against the growing chloroma. Immunisation with the PPD tuberculin, on the other hand, favorably influenced the host's immune system thus contributing to the tumor rejection and the development of pronounced host response in a high percentage of cases. The results were discussed in the light of favorable experiences gained with this mode of cancer immunotherapy in a number of clinical trials, as well as in a previous experimental DBA/2 mouse mastocytoma model. This apparent controversy between the previously obtained and the present results was interpreted to be caused by the different antigenic properties of the tumors used in these studies. The importance of the selection of an appropriate model system was emphasized, when it was attempted to obtain data relevant to human tumors for experimental cancer immunotherapy systems.
 ...
PMID:The use of polymerised autologous tumor tissue particles for experimental cancer immunotherapy in rats bearing Shay chloroma. 694 5

Recent findings implied that the progression of hematologic malignancies, like that of solid tumors, is dependent on neovascularization. Recent studies on patients with acute myeloid leukemia (AML) showed increased levels of leukocyte-associated vascular endothelial growth factor (VEGF) and neovascularization of the bone marrow. Murine (32D, M1) and human (HEL, U937, and UKE-1) leukemic cell lines and freshly isolated leukemic cells were analyzed for the expression of VEGF and VEGF receptor mRNA. The expression of VEGF and VEGF receptors KDR and neuropilin-1 (NRP-1) was detected in these cells. In a murine chloroma model, delivery of VEGF(165) using microencapsulation technology resulted in enhanced tumor growth and vascularization, whereas treatment with a VEGF antagonist soluble NRP-1 (sNRP-1) inhibited tumor angiogenesis and growth. In a systemic leukemia model, survival of mice injected with adenovirus (Ad) encoding for Fc-sNRP-1 (sNRP-1 dimer) was significantly prolonged as compared with mice injected with Ad-LacZ. Further analyses showed a reduction in circulating leukemic cells and infiltration of liver and spleen as well as bone marrow neovascularization and cellularity. Taken together, these results demonstrate that angiogenic factors such as VEGF promote AML progression in vivo. The use of VEGF antagonists as an antiangiogenesis approach offers a potential treatment for AML. Finally, our novel in vivo drug delivery model may be useful for testing the activities of other peptide antiangiogenic factors.
 ...
PMID:In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. 1245 80

To assess clinical outcome of patients with pacemaker treated with thoracic radiation therapy for T8-T9 paravertebral chloroma. A 92-year-old male patient with chloroma presenting as paravertebral painful and compressive (T8-T9) mass was referred for radiotherapy in the Department of Radiation Oncology, Institut Curie. The patient presented with cardiac dysfunction and a permanent pacemaker that had been implanted prior. The decision of Multidisciplinary Meeting was to deliver 30 Gy in 10 fractions for reducing the symptoms and controlling the tumor growth. The patient received a total dose of 30 Gy in 10 fractions using 4-field conformal radiotherapy with 20-MV photons. The dose to pacemaker was 0.1 Gy but a part of the pacing leads was in the irradiation fields. The patient was treated the first time in the presence of his radiation oncologist and an intensive care unit doctor. Moreover, the function of his pacemaker was monitored during the entire radiotherapy course. No change in pacemaker function was observed during any of the radiotherapy fractions. The radiotherapy was very well tolerated without any side effects. The function of the pacemaker was checked before and after the radiotherapy treatment by the cardiologist and no pacemaker dysfunction was observed. Although updated guidelines are needed with acceptable dose criteria for implantable cardiac devices, it is possible to treat patients with these devices and parts encroaching on the radiation field. This case report shows we were able to safely treat our patient through a multidisciplinary approach, monitoring the patient during each step of the treatment.
 ...
PMID:Case study thoracic radiotherapy in an elderly patient with pacemaker: the issue of pacing leads. 2220 62